After multiple criticisms after the acquisition of the Sputnik V Vaccine against COVID-19, it was the embassy of the Russian Federation who provided some explanations.

Through their official social networks, the Russian embassy assured that “a lot of false information about the vaccine has been spread”, so they decided “disprove some myths on the biological developed by the Gamaleya National Center for Epidemiology and Microbiology”.

First, they indicated that the myth that their vaccines are of poor quality, as they assured that the said Center, founded in 1891, is a leading institution in its sphere worldwide.

“In 2015, it successfully developed and registered two Ebola vaccines, using the adenoviral vector platform (same that is used in Sputnik V)”, rhey reported, based on information from the Center itself.

In addition, they noted that the results of phases I and II of his clinical trial were published in the international journal The Lancet, one of the most prestigious in the medical and scientific field.

Secondly, they assured that the argument of not being “proven to work in practice”. To do this, they stated that “in a post-marketing clinical study of phase III, double-blind, randomized, and placebo-controlled vacuna Sputnik V40 thousand volunteers participated ”.

In addition, they clarified that it has already been administered to 1.5 million people in the world, and in September 2020 the Minister of Defense in Russia was vaccinated, Sergei Shoigu as well as one of the president’s daughters..

The possible acquisition of the Russian vaccine by the Mexican authorities has started an important debate in Mexico Photo: Andrey Rudakov / Bloomberg

The possible acquisition of the Russian vaccine by the Mexican authorities has started an important debate in Mexico. 

Regarding the results of phase III clinical trials, they reported that “these are close to being published”. For this information, they relied on various publications, videos and international news.

On the other hand, it circulated that “only Mexico, Belarus, Venezuela and Argentina bet on the Russian vaccine”. This, they considered, is also a false saying.

In that context, they stated that the president himself “Vladimir Putin revealed that the vaccine has the sanitary authorization of 13 countries”, in addition to having a purchase of “up to 1,200 million doses for 50 different nations”, as reported by the Russian Direct Investment Fund.

In addition, they pointed out the information about the supposed null approval of the scientific community at the international level, because even within the World Health Organization (WHO) “It is on the list among the top 10 candidate vaccines approaching the end of clinical trials and the start of mass production.”

Finally, they assured that it is true that it is a cheap vaccine, as Mexican legislators and legislators assured, but they considered that there is nothing wrong with it being economically more accessible than others.

G3HUF7XQEZCURNQCWPRI2X7DSQ

“Fake News”: this is how the Russian embassy in Mexico denied the myths and criticism surrounding the Sputnik V vaccine.
 

The Mexican authorities, for their part, are already preparing for the acquisition of 24 million doses of Sputnik V vaccines, according to the president of Mexico, Andrés Manuel López Obrador and the Secretary of the Treasury, Arturo Herrera.

During his visit to Mazatlán, Herrera insisted that they will be invested 4.8 billion pesos will be invested for the purchase of 24 million doses of Sputnik V, which will serve to immunize up to 12 million Mexicans, since it requires a couple of doses, reported The universal.

In addition, the public official assured that Mexico has about 32 billion pesos for the purchase of vaccines. This investment, he said, will seek to ensure the immunization for 90 million people over 18 years of age, according to journalist Javier Cabrera Martínez.

For its part, Lopez Obrador confirmed that these doses were agreed “for the next two months” by him and his Russian counterpart Vladimir Putin.

Categorized in:

Tagged in: